Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Benzinga · 1d ago
Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.